"Achieving a nearly 10 mmHg reduction in systolic blood pressure with baxdrostat in the BaxHTN phase-3 trial is exciting, as this level of reduction is linked to substantially lower risk of heart attack, stroke, heart failure and kidney disease. I think this could be a gamechanger in the way we approach difficult to control or hard to control blood pressure. The results suggest that this drug could help up to half a billion people globally."
"The results of the BaxHTN study, which involved 796 patients from 214 clinics worldwide, showed that after 12 weeks, patients taking baxdrostat saw their blood pressure fall by about 9-10 mmHg (millimetres of mercury, the unit of measurement of blood pressure) more than placebo a reduction large enough to cut cardiovascular risk. About four in 10 patients taking the drug 1mg (39.4%) or 2mg (40%) once daily in tablet form reached healthy blood pressure levels, compared with fewer than two in 10 (18.7%) on placebo."
More than 1.3 billion people worldwide have hypertension and about half have uncontrolled or treatment-resistant blood pressure, increasing risks of heart attack, stroke, kidney disease and early death. The BaxHTN phase-3 trial enrolled 796 patients across 214 clinics to evaluate baxdrostat for difficult-to-control hypertension. After 12 weeks, baxdrostat lowered systolic blood pressure by roughly 9–10 mmHg more than placebo, a magnitude associated with substantially lower cardiovascular risk. Approximately 39–40% of patients on 1mg or 2mg reached healthy blood pressure, versus 18.7% with placebo. The trial was presented at the European Society of Cardiology congress and sponsored by AstraZeneca.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]